top of page
clopidosafe_background image.jpg

Clopidosafe™ 
Enhance Your Treatment with Pharmacogenetic Testing 

Clopidosafe™  — Enhance Your Treatment with Pharmacogenetic Testing 

Understanding Clopidogrel and Clopidosafe™ 

Clopidogrel is a vital antiplatelet medication that helps prevent blood clots by inhibiting platelets from clumping together, thus reducing the risk of stroke or heart attack. The efficacy of Clopidogrel is significantly influenced by genetic variations, particularly in the CYP2C19 gene1. These variations can affect the metabolic activation of the drug, leading to variations in treatment outcomes2. 

Introducing Clopidosafe™ 

Our pharmacogenetic test, Clopidosafe™, is designed to identify these genetic variants, providing crucial insights into how well your body will respond to Clopidogrel. By understanding your unique genetic makeup, Clopidosafe™ can help ensure that you receive the most effective dosage for optimal health outcomes. 

Potential Consequences of Varied Drug Efficacy 

Without personalized testing, patients may not experience the full benefits of Clopidogrel, potentially leading to an increased risk of cardiovascular events. Clinical trials showed that patients with genotyped-guided P2Y12 inhibitor therapy after percutaneous coronary intervention had lower ischemic events compared to conventional therapy and similar net adverse clinical outcomes but decreased risk of major or minor bleeding compared with prasugrel or tricagrelor treatment3,4. Clopidosafe™ aims to mitigate this risk by tailoring your treatment plan to your genetic profile.  

clopidosafe_1_ENG.png

Genetic-guided therapy resulted in a statistically significant 40% reduction in cumulative ischemic events compared with conventional clopidogrel therapy.

Interpreting Your Clopidosafe™ Results 

Understanding your Clopidosafe™ test results is key to optimizing your treatment with Clopidogrel. Here’s a breakdown of what the results mean: 

clopidosafe_2_ENG.png

Next Steps 

Discuss your results with your healthcare provider to determine the best course of action. Your provider may suggest further tests, a modified treatment plan, or additional preventive measures based on your genetic profile and other factors associated with high on-treatment residual platelet aggregation. 

Why Choose Clopidosafe™? 

BChealth_content_1(white).png
Customized treatment strategies based on your DNA
Personalized Medicine
BChealth_content_1(white).png
 Maximize the benefits of your medication
Enhanced Efficacy
BChealth_content_1(white).png
 Empower your decisions with
genetic knowledge 
Informed Healthcare

Complete Your Journey with GemVCare

How it works

Specimens will be sent to our testing center for analysis and the test will be completed within 14 working days.
02
01
Collect specimens at designated centers

•Oral cell specimen / Blood specimen 

03
Reports will be explained by your healthcare provider and an appropriate disease management plan will be designed accordingly.  
layout_circle_2.png
​在指定中心抽取樣本
樣本於檢測中心進行分析
由醫療保健提供者講解報告

References:

  1. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22;360(4):354-62.  

  2. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27;304(16):1821-30. 

  3. Ingraham BS, Farkouh ME, Lennon RJ, So D, Goodman SG, Geller N, Bae JH, Jeong MH, Baudhuin LM, Mathew V, Bell MR, Lerman A, Fu YP, Hasan A, Iturriaga E, Tanguay JF, Welsh RC, Rosenberg Y, Bailey K, Rihal C, Pereira NL. Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2023 Apr 10;16(7):816-825.  

  4. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Postma MJ, de Boer A, Boersma C, Deneer VHM, Ten Berg JM. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med. 2019 Oct 24;381(17):1621-1631. 

bottom of page